NATCO PHARMA
Quarterly Results Analysis [Jun2026]
NATCO PHARMA Quarterly Results
| Consolidated | Jun2026 UnAudited |
Mar2026 UnAudited |
Dec2025 UnAudited |
Sep2025 UnAudited |
Jun2025 UnAudited |
Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
|---|---|---|---|---|---|---|---|---|
| Revenues | ₹735 Cr | ₹739 Cr | ₹647 Cr | ₹1,363 Cr | ₹1,329 Cr | ₹1,221 Cr | ₹475 Cr | ₹1,371 Cr |
| Expenses | ₹549 Cr | ₹612 Cr | ₹489 Cr | ₹784 Cr | ₹758 Cr | ₹673 Cr | ₹436 Cr | ₹567 Cr |
| Operating Income | ₹187 Cr | ₹128 Cr | ₹159 Cr | ₹579 Cr | ₹571 Cr | ₹548 Cr | ₹39 Cr | ₹804 Cr |
| Other Income | ₹59 Cr | ₹78 Cr | ₹58 Cr | ₹100 Cr | ₹62 Cr | ₹66 Cr | ₹176 Cr | ₹64 Cr |
| Interest | ₹13 Cr | ₹11 Cr | ₹10 Cr | ₹13 Cr | ₹3 Cr | ₹10 Cr | ₹4 Cr | ₹4 Cr |
| Depreciation | ₹47 Cr | ₹50 Cr | ₹46 Cr | ₹52 Cr | ₹58 Cr | ₹98 Cr | ₹47 Cr | ₹46 Cr |
| Profit Before Tax | ₹186 Cr | ₹144 Cr | ₹161 Cr | ₹614 Cr | ₹572 Cr | ₹506 Cr | ₹164 Cr | ₹818 Cr |
| Profit After Tax | ₹122 Cr | ₹233 Cr | ₹140 Cr | ₹518 Cr | ₹480 Cr | ₹406 Cr | ₹132 Cr | ₹677 Cr |
| EPS | ₹11.54 | ₹14.97 | ₹8.46 | ₹28.96 | ₹26.85 | ₹22.72 | ₹7.43 | ₹37.84 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NATCO PHARMA | -1.8% | -8.1% | -2.1% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.7% | -1.4% | 21.7% |
| DIVIS LABORATORIES | 2% | 10.3% | 49.5% |
| TORRENT PHARMACEUTICALS | -0.4% | -0.5% | 38.6% |
| CIPLA | -0.5% | -2.5% | -10.2% |
| DR REDDYS LABORATORIES | -1.2% | 0% | -7.1% |
| MANKIND PHARMA | -1.5% | -3.3% | -4.6% |
| LUPIN | -0.6% | -9.4% | 13% |
| ZYDUS LIFESCIENCES | -3.2% | 2.9% | 19.2% |
NATCO PHARMA Quarterly Revenues
| Revenues | |
|---|---|
| Q-o-Q | -0.53 % |
| Y-o-Y | -44.68 % |
| Quarters | Revenues | % Change | |
|---|---|---|---|
| Jun2026 | ₹735 Cr | -0.53 | |
| Mar2026 | ₹739 Cr | 14.18 | |
| Dec2025 | ₹647 Cr | -52.51 | |
| Sep2025 | ₹1,363 Cr | 2.57 | |
| Jun2025 | ₹1,329 Cr | 8.84 | |
| Mar2025 | ₹1,221 Cr | 157.16 | |
| Dec2024 | ₹475 Cr | -65.37 | |
| Sep2024 | ₹1,371 Cr | - | |
NATCO PHARMA Quarterly Operating Profit
| Operating Profit | |
|---|---|
| Q-o-Q | 46.16 % |
| Y-o-Y | -67.34 % |
| Quarters | Operating Profit | % Change | |
|---|---|---|---|
| Jun2026 | ₹187 Cr | 46.16 | |
| Mar2026 | ₹128 Cr | -19.60 | |
| Dec2025 | ₹159 Cr | -72.60 | |
| Sep2025 | ₹579 Cr | 1.44 | |
| Jun2025 | ₹571 Cr | 4.18 | |
| Mar2025 | ₹548 Cr | 1,312.63 | |
| Dec2024 | ₹39 Cr | -95.18 | |
| Sep2024 | ₹804 Cr | - | |
| Operating Margins | |
|---|---|
| Q-o-Q | 46.99 % |
| Y-o-Y | -40.96 % |
| Quarters | Operating Margin% | % Change | |
|---|---|---|---|
| Jun2026 | 25.37% | 46.99 | |
| Mar2026 | 17.26% | -29.61 | |
| Dec2025 | 24.52% | -42.29 | |
| Sep2025 | 42.49% | -1.12 | |
| Jun2025 | 42.97% | -4.28 | |
| Mar2025 | 44.89% | 449.45 | |
| Dec2024 | 8.17% | -86.07 | |
| Sep2024 | 58.66% | - | |
NATCO PHARMA Quarterly Profit After Tax
| Profit After Tax(PAT) | |
|---|---|
| Q-o-Q | -47.62 % |
| Y-o-Y | -74.56 % |
| Quarters | Profit After Tax | % Change | |
|---|---|---|---|
| Jun2026 | ₹122 Cr | -47.62 | |
| Mar2026 | ₹233 Cr | 66.17 | |
| Dec2025 | ₹140 Cr | -72.89 | |
| Sep2025 | ₹518 Cr | 7.83 | |
| Jun2025 | ₹480 Cr | 18.30 | |
| Mar2025 | ₹406 Cr | 206.65 | |
| Dec2024 | ₹132 Cr | -80.43 | |
| Sep2024 | ₹677 Cr | - | |
| PAT Margins | |
|---|---|
| Q-o-Q | -47.36 % |
| Y-o-Y | -54.01 % |
| Quarters | PAT Margin(%) | % Change | |
|---|---|---|---|
| Jun2026 | 16.62 % | -47.36 | |
| Mar2026 | 31.57 % | 45.55 | |
| Dec2025 | 21.69 % | -42.92 | |
| Sep2025 | 38 % | 5.15 | |
| Jun2025 | 36.14 % | 8.69 | |
| Mar2025 | 33.25 % | 19.22 | |
| Dec2024 | 27.89 % | -43.47 | |
| Sep2024 | 49.34 % | - | |
NATCO PHARMA Quarterly Earnings Per Share (EPS)
| EPS | |
|---|---|
| Q-o-Q | -22.91 % |
| Y-o-Y | -57.02 % |
| Quarters | EPS | % Change | |
|---|---|---|---|
| Jun2026 | ₹11.54 | -22.91 | |
| Mar2026 | ₹14.97 | 76.95 | |
| Dec2025 | ₹8.46 | -70.79 | |
| Sep2025 | ₹28.96 | 7.86 | |
| Jun2025 | ₹26.85 | 18.18 | |
| Mar2025 | ₹22.72 | 205.79 | |
| Dec2024 | ₹7.43 | -80.36 | |
| Sep2024 | ₹37.84 | - | |
You may also like the below Video Courses